Q4 2022 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Immunology
ScemblixⓇ - BCR-ABL inhibitor
NCT04971226 ASC4FIRST (CABL001J12301)
Chronic myeloid leukemia, 1st line
Phase 3
Indication
Phase
Patients
402
Primary
Outcome
Major Molecular Response (MMR) at week 48
Measures
2023 priorities
Innovation: Clinical trials
Neuroscience
Arms
Intervention
Arm 1: asciminib 80 mg QD
Arm 2: Investigator selected TKI including one of the below treatments:
- Imatinib 400 mg QD
- Nilotinib 300 mg BID
-
- Dasatinib 100 mg QD
- Bosutinib 400 mg QD
Patients with newly diagnosed philadelphia chromosome positive chronic
myelogenous leukemia in chronic phase
Target
Patients
Readout
Milestone(s)
2024
Publication
TBD
93 Investor Relations | Q4 2022 Results
Oncology
Appendix
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation